Unnamed: 0,title,date,stock,sentiment
534210.0,Galectin Therapeutics Inc Files For Mixed Shelf Of Up To $100M,2020-05-11 07:53:00-04:00,GALT,neutral
534211.0,Galectin Therapeutics Q1 EPS $(0.060) Up From $(0.200) YoY,2020-05-11 07:53:00-04:00,GALT,neutral
534212.0,72 Biggest Movers From Yesterday,2020-05-01 05:29:00-04:00,GALT,neutral
534213.0,61 Stocks Moving In Thursday's Mid-Day Session,2020-04-30 12:43:00-04:00,GALT,neutral
534214.0,Mid-Day Market Update: Crude Oil Surges 20%; Chesapeake Energy Shares Plunge,2020-04-30 12:28:00-04:00,GALT,negative
534215.0,Galectin Therapeutics Reports Submission Of Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol In NASH Cirrhosis,2020-04-30 09:02:00-04:00,GALT,neutral
534216.0,108 Biggest Movers From Yesterday,2020-04-30 05:30:00-04:00,GALT,neutral
534217.0,"B. Riley FBR Maintains Buy on Galectin Therapeutics, Lowers Price Target to $4",2020-04-03 07:46:00-04:00,GALT,negative
534218.0,Galectin Therapeutics Warns Plans To Initiate NASH-RX Trial In Q2 Could Be Impacted By Coronavirus Outbreak,2020-04-02 08:18:00-04:00,GALT,negative
534219.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,GALT,positive
534220.0,"HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Lowers Price Target to $9",2020-03-17 07:34:00-04:00,GALT,negative
534221.0,"Galectin Therapeutics Says Expects It Will Require More Cash To Fund Operations After Sept 30, 2021",2020-03-16 08:00:00-04:00,GALT,neutral
534222.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,GALT,negative
534223.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,GALT,neutral
534224.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,GALT,negative
534225.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,GALT,positive
534226.0,Stocks That Hit 52-Week Lows On Wednesday,2020-02-26 11:14:00-05:00,GALT,negative
534227.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,GALT,negative
534228.0,94 Biggest Movers From Yesterday,2020-02-12 05:13:00-05:00,GALT,neutral
534229.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,GALT,positive
534230.0,Stocks That Hit 52-Week Lows On Monday,2020-02-10 10:28:00-05:00,GALT,negative
534231.0,13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market,2020-02-05 16:11:00-05:00,GALT,neutral
534232.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,GALT,negative
534233.0,Stocks That Hit 52-Week Lows On Friday,2020-01-31 11:00:00-05:00,GALT,negative
534234.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,GALT,negative
534235.0,Stocks That Hit 52-Week Lows On Thursday,2020-01-30 10:54:00-05:00,GALT,negative
534236.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,GALT,positive
534237.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,GALT,neutral
534238.0,Stocks That Hit 52-Week Lows On Tuesday,2020-01-28 11:09:00-05:00,GALT,negative
534239.0,Stocks That Hit 52-Week Lows On Friday,2019-12-20 12:13:00-05:00,GALT,negative
534240.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,GALT,negative
534241.0,Stocks That Hit 52-Week Lows On Tuesday,2019-12-10 14:29:00-05:00,GALT,negative
534242.0,Galectin Therapeutics' Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin Published in Gastroenterology,2019-12-09 08:00:00-05:00,GALT,neutral
534243.0,Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis,2019-12-05 12:06:00-05:00,GALT,neutral
534244.0,74 Biggest Movers From Yesterday,2019-11-13 04:42:00-05:00,GALT,neutral
534245.0,Galectin Therapeutics Q3 EPS $(0.05) Up From $(0.07) YoY,2019-11-12 09:11:00-05:00,GALT,neutral
534246.0,"Galectin Therapeutics Reports Deal With Siemens Healthineers For NASH, Liver Fibrosis Collaboration",2019-11-11 09:47:00-05:00,GALT,neutral
534247.0,52 Biggest Movers From Yesterday,2019-09-19 05:18:00-04:00,GALT,neutral
534248.0,"Galectin Therapeutics, Providence Cancer Institute Receive Patent On Use Of Belapectin In Cancer Immunotherapy",2019-09-17 08:22:00-04:00,GALT,negative
534249.0,64 Biggest Movers From Friday,2019-09-09 05:43:00-04:00,GALT,neutral
534250.0,Stocks That Hit 52-Week Lows On Friday,2019-08-23 11:08:00-04:00,GALT,negative
534251.0,Galectin Therapeutics S-3 Shows Registration For ~1.7M Common Stock Offering,2019-08-09 16:39:00-04:00,GALT,neutral
534252.0,Galectin Therapeutics Q2 EPS $(0.06) Up From $(0.11) YoY,2019-08-09 08:06:00-04:00,GALT,neutral
534253.0,Stocks That Fell Through 52-Week Lows Wednesday,2019-08-07 14:22:00-04:00,GALT,negative
534254.0,Galectin Therapeutics Submits Phase 3 NASH-RX Protocol In Nash Cirrhosis To FDA,2019-08-05 08:11:00-04:00,GALT,neutral
534255.0,30 Stocks Moving In Tuesday's Pre-Market Session,2019-06-18 08:29:00-04:00,GALT,neutral
534256.0,Galectin Therapeutics Raises $44.5M In Rights Offering And $2.5M From Warrant Exercise,2019-05-28 09:07:00-04:00,GALT,neutral
534257.0,Galectin Therapeutics Reports Alternate Price Of Common Stock In Rights Offering,2019-05-23 17:32:00-04:00,GALT,neutral
534258.0,Galectin Therapeutics Q1 EPS $(0.2) Misses $(0.14) Estimate,2019-05-10 08:00:00-04:00,GALT,negative
534259.0,42 Biggest Movers From Yesterday,2019-04-30 07:05:00-04:00,GALT,neutral
534260.0,52 Biggest Movers From Yesterday,2019-04-24 05:11:00-04:00,GALT,neutral
534261.0,"Galectin Therapeutics Reports Co., Providence Cancer Institute Presented Highlights Showing Improved Response Of T Cells Seen In Combo Immunotherapy For Cancer Using GR-MD-02",2019-03-22 10:24:00-04:00,GALT,negative
534262.0,UPDATE: Galectin Chair Announces Rights Offering,2019-03-06 08:05:00-05:00,GALT,neutral
534263.0,Galectin Therapeutics Reports Chair Richard Uihlein Sent Open Letter To Shareholders,2019-03-06 08:04:00-05:00,GALT,neutral
534264.0,Galectin Therapeutics Files For Rights Offering,2019-03-06 08:01:00-05:00,GALT,neutral
534265.0,75 Biggest Movers From Yesterday,2019-02-21 05:12:00-05:00,GALT,neutral
534266.0,"Benzinga's Top Upgrades, Downgrades For February 13, 2019",2019-02-13 09:11:00-05:00,GALT,positive
534267.0,"B. Riley FBR Initiates Coverage On Galectin Therapeutics with Buy Rating, Announces $11 Price Target",2019-02-13 07:05:00-05:00,GALT,neutral
534268.0,65 Biggest Movers From Yesterday,2019-01-08 05:16:00-05:00,GALT,neutral
534269.0,50 Biggest Movers From Monday,2019-01-02 04:48:00-05:00,GALT,neutral
534270.0,Galecin Therapeutics Shares Resume Trading Up 12.75%,2018-12-24 10:20:00-05:00,GALT,positive
534271.0,60 Biggest Movers From Yesterday,2018-12-21 05:11:00-05:00,GALT,neutral
534272.0,Galectin Therapeutics Announces Extension Of $10M Line Credit,2018-12-20 08:34:00-05:00,GALT,positive
534273.0,Galectin Therapeutics 8-K Shows Co. Received 1-Year Extension For Its $10M Credit Facility,2018-12-20 08:29:00-05:00,GALT,positive
534274.0,Galectin Therapeutics Inc. Q3 EPS $(0.07) Beats $(0.09) Estimate,2018-11-13 08:17:00-05:00,GALT,neutral
534275.0,75 Biggest Movers From Yesterday,2018-11-07 04:00:00-05:00,GALT,neutral
534276.0,52 Biggest Movers From Yesterday,2018-11-06 05:52:00-05:00,GALT,neutral
534277.0,42 Stocks Moving In Monday's Mid-Day Session,2018-11-05 12:23:00-05:00,GALT,neutral
534278.0,Galectin Therapeutics Form 424B3 Shows Shows Registration For ~6.95M Shares Common Stock Offering By Selling Shareholders,2018-09-25 12:35:00-04:00,GALT,positive
534279.0,52 Biggest Movers From Friday,2018-09-24 06:22:00-04:00,GALT,neutral
534280.0,40 Stocks Moving In Friday's Mid-Day Session,2018-09-21 12:38:00-04:00,GALT,neutral
534281.0,56 Biggest Movers From Yesterday,2018-09-21 04:48:00-04:00,GALT,neutral
534282.0,'The $GALT stock promoters (many of the same involved with the $AMPE pump and dump) have been salivating in anticipation of these meaningless single-arm combo data. Day traders enjoy!' -Tweet From STAT News' Adam Feuerstein,2018-09-20 08:11:00-04:00,GALT,negative
534283.0,Galectin Therapeutics Reports Combo Immunotherapy Of GR-MD-02 And Keytruda For All Cohorts Reported Showed An Objective Response Rate Of 50% (7/14 Patients),2018-09-20 08:03:00-04:00,GALT,neutral
534284.0,28 Stocks Moving In Monday's Pre-Market Session,2018-09-17 08:02:00-04:00,GALT,neutral
534285.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,GALT,neutral
534286.0,52 Biggest Movers From Friday,2018-09-10 05:21:00-04:00,GALT,neutral
534287.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,GALT,neutral
534288.0,44 Stocks Moving In Friday's Mid-Day Session,2018-09-07 12:54:00-04:00,GALT,neutral
534289.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2018-09-02 09:41:00-04:00,GALT,neutral
534290.0,Galectin Therapeutics Option Alert: Sep 21 $8 Calls Sweep (24) above Ask!: 1000 @ $0.559 vs 1602 OI; Ref=$6.29,2018-08-31 15:08:00-04:00,GALT,positive
534291.0,62 Biggest Movers From Yesterday,2018-08-31 05:19:00-04:00,GALT,neutral
534292.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-08-30 12:44:00-04:00,GALT,neutral
534293.0,45 Biggest Movers From Yesterday,2018-08-30 05:38:00-04:00,GALT,neutral
534294.0,41 Biggest Movers From Yesterday,2018-08-21 04:47:00-04:00,GALT,neutral
534295.0,60 Biggest Movers From Yesterday,2018-08-16 04:56:00-04:00,GALT,neutral
534296.0,55 Stocks Moving In Wednesday's Mid-Day Session,2018-08-15 12:40:00-04:00,GALT,neutral
534297.0,Galectin Therapeutics Q2 EPS $(0.11) Beats $(0.12) Estimate,2018-08-14 08:00:00-04:00,GALT,neutral
534298.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,GALT,neutral
534299.0,42 Biggest Movers From Yesterday,2018-07-06 04:18:00-04:00,GALT,neutral
534300.0,42 Biggest Movers From Yesterday,2018-06-28 05:44:00-04:00,GALT,neutral
534301.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-06-27 13:04:00-04:00,GALT,neutral
534302.0,Mid-Day Market Update: Crude Oil Up Over 3%; Aquinox Pharmaceuticals Shares Plunge,2018-06-27 12:33:00-04:00,GALT,negative
534303.0,Mid-Morning Market Update: Markets Open Higher; Conagra To Acquire Pinnacle Foods,2018-06-27 10:39:00-04:00,GALT,neutral
534304.0,"Galectin Therapeutics Reports Received Patent For GR-MD-02 Patent For Method, Treatment Of Pulmonary Fibrosis",2018-06-27 08:07:00-04:00,GALT,neutral
534305.0,54 Biggest Movers From Yesterday,2018-06-27 04:51:00-04:00,GALT,neutral
534306.0,50 Biggest Movers From Yesterday,2018-06-21 04:34:00-04:00,GALT,neutral
534307.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-06-20 12:23:00-04:00,GALT,neutral
534308.0,"Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares",2018-06-19 08:08:00-04:00,GALT,positive
534309.0,"Galectin Therapeutics Earlier 8-K Shows Pres, CEO Peter Traber Resigned; Harold Shlevin Named Replacement",2018-06-15 10:03:00-04:00,GALT,negative
534310.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,GALT,neutral
534311.0,"Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi",2018-06-14 08:11:00-04:00,GALT,negative
534312.0,38 Biggest Movers From Yesterday,2018-06-14 04:17:00-04:00,GALT,neutral
534313.0,Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide,2018-06-13 12:03:00-04:00,GALT,positive
534314.0,Galectin Therapeutics Names COO Harold Shlevin CEO,2018-06-12 08:35:00-04:00,GALT,neutral
534315.0,36 Biggest Movers From Friday,2018-06-11 04:37:00-04:00,GALT,neutral
534316.0,Galectin Therapeutics Shares Spike Higher; Traders Attributing To Article 'Galectin Therapeutics's Market Value Should Soar In The Coming Months',2018-06-07 11:53:00-04:00,GALT,positive
534317.0,Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board,2018-06-04 09:01:00-04:00,GALT,neutral
534318.0,48 Biggest Movers From Yesterday,2018-05-15 04:26:00-04:00,GALT,neutral
534319.0,Mid-Afternoon Market Update: Precipio Surges Following Strong Preliminary Q1 Results; aTyr Pharma Shares Slide,2018-05-14 14:29:00-04:00,GALT,positive
534320.0,36 Stocks Moving In Monday's Mid-Day Session,2018-05-14 12:50:00-04:00,GALT,neutral
534321.0,Galectin Therapeutics Shares Up 34% After Co. Announced It Would Proceed With Phase 3 Development Of GR-MD-02 For NASH Cirrhosis Following FDA Meeting,2018-05-14 12:17:00-04:00,GALT,positive
534322.0,Mid-Day Market Update: Dow Rises 140 Points; Remark Holdings Shares Plunge,2018-05-14 12:14:00-04:00,GALT,positive
534323.0,Galectin Therapeutics Reports Will Proceed To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis,2018-05-14 09:07:00-04:00,GALT,neutral
534324.0,Galectin Therapeutics Q1 EPS $(0.12) Beats $(0.13) Estimate,2018-05-11 16:12:00-04:00,GALT,neutral
534325.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-04-24 08:01:00-04:00,GALT,neutral
534326.0,32 Biggest Movers From Yesterday,2018-04-20 05:42:00-04:00,GALT,neutral
534327.0,41 Biggest Movers From Yesterday,2018-04-13 05:04:00-04:00,GALT,neutral
534328.0,8 Biotech Stocks With Clinical Trial Outcomes In April,2018-04-05 15:30:00-04:00,GALT,neutral
534329.0,36 Biggest Movers From Yesterday,2018-04-05 04:40:00-04:00,GALT,neutral
534330.0,41 Biggest Movers From Yesterday,2018-04-03 04:18:00-04:00,GALT,neutral
534331.0,33 Stocks Moving In Monday's Mid-Day Session,2018-04-02 12:53:00-04:00,GALT,neutral
534332.0,41 Biggest Movers From Thursday,2018-04-02 05:21:00-04:00,GALT,neutral
534333.0,Mid-Afternoon Market Update: NASDAQ Up 2%; Movado Shares Surge On Earnings Beat,2018-03-29 14:33:00-04:00,GALT,positive
534334.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-03-29 12:21:00-04:00,GALT,neutral
534335.0,Mid-Day Market Update: Dow Rises Over 1%; Zosano Pharma Shares Plummet,2018-03-29 12:10:00-04:00,GALT,positive
534336.0,"Galectin Therapeutics Shares Up 19.3% After Co. Reported Better-Than-Expected Q4 Loss, Announces Strong Cash Position and Mentioned Ongoing Discussions With Potential Pharma Partners",2018-03-29 12:01:00-04:00,GALT,positive
534337.0,"UPDATE: Galectin Says Believes It Has Sufficient Cash To Fund Currently-Planned Operations, R&D Activities Through At Least Mar. 31, 2019",2018-03-29 08:15:00-04:00,GALT,neutral
534338.0,Galectin Therapeutics FY17 EPS $(0.49) Beats $(0.53) Est.; Says Co. Continues To Remain In Ongoing Discussions With A Number Of Pharma Cos. About Potential Partnerships,2018-03-29 08:14:00-04:00,GALT,positive
534339.0,56 Biggest Movers From Yesterday,2018-03-09 04:51:00-05:00,GALT,neutral
534340.0,35 Stocks Moving In Monday's Mid-Day Session,2018-01-29 12:21:00-05:00,GALT,neutral
534341.0,"Galectin Therapeutics Shares Down 3.2%; Co. Earlier Announced It Was Granted Patents In China, Japan For Supporting NASH, Cancer Immunotherapy Clinical Development Programs",2018-01-25 11:12:00-05:00,GALT,positive
534342.0,48 Biggest Movers From Yesterday,2018-01-09 06:07:00-05:00,GALT,neutral
534343.0,40 Biggest Movers From Yesterday,2018-01-04 05:30:00-05:00,GALT,neutral
534344.0,"Galectin Therapeutics Shares Up 11.09%; After Dropping ~80% After Failed Phase 2b Trial Dec. 5, Stock Has Made New 52-Week High Of $4.80 Today, Trading 78% Above Closing Price Day Before Drug Failure News, With No News To Justify",2018-01-03 15:12:00-05:00,GALT,negative
534345.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-01-03 12:26:00-05:00,GALT,neutral
534346.0,Galectin Therapeutics Option Alert: Apr 20 $3 Calls Sweep (5) at the Bid: 1200 @ $0.85 vs 1027 OI; Ref=$3.52,2017-12-29 14:44:00-05:00,GALT,positive
534347.0,30 Biggest Movers From Yesterday,2017-12-28 05:01:00-05:00,GALT,neutral
534348.0,Galectin Therapeutics Announces $10M Credit Line Sufficient To Cover Expenditures Into 2019,2017-12-19 16:10:00-05:00,GALT,positive
534349.0,40 Biggest Movers From Yesterday,2017-12-19 05:15:00-05:00,GALT,neutral
534350.0,UPDATE: Galectin Says 'Approximately 50% of all patients with NASH cirrhosis do not have esophageal varices which demonstrates a large potentially addressable population',2017-12-14 09:31:00-05:00,GALT,neutral
534351.0,"Galectin Therapeutics Offers Update At Annual Meeting: CEO Reviews Results Of NASH-CX Trial Which Showed Statistically Significant, Clinically Meaningful Effects In Patients Who Had NASH Cirrhosis But Did Not Have Esophageal Varices",2017-12-14 09:31:00-05:00,GALT,positive
534352.0,36 Biggest Movers From Friday,2017-12-11 06:02:00-05:00,GALT,neutral
534353.0,"Galectin Therapeutics Director Marc Rubin Buys 7,000 @ Avg Price: $1.85 -Form4",2017-12-08 14:28:00-05:00,GALT,neutral
534354.0,Galectin  Option Alert: Jan 19 $2 Puts Sweep (3) at the Bid: 1009 @ $0.401 vs 2307 OI; Ref=$2.15 Signals,2017-12-08 10:26:00-05:00,GALT,positive
534355.0,"Adam Feuerstein Tweets: Re: $GALT â€” H.C. Wainwright published today one of the most embarrassing research notes you'll ever read. This is what they do. And yes, a stock offering is obviously coming.",2017-12-07 13:13:00-05:00,GALT,neutral
534356.0,Galectin Option Alert: Dec 15 $2 Puts Sweep (6) at the Ask: 1000 @ $0.351 vs 5195 OI; Ref=$2.06,2017-12-07 12:45:00-05:00,GALT,positive
534357.0,Galectin Therapeutics Spikes to High of $2.05 on Volume,2017-12-07 12:18:00-05:00,GALT,neutral
534358.0,36 Biggest Movers From Yesterday,2017-12-06 05:19:00-05:00,GALT,neutral
534359.0,Mid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain,2017-12-05 14:31:00-05:00,GALT,positive
534360.0,30 Stocks Moving In Tuesday's Mid-Day Session,2017-12-05 13:59:00-05:00,GALT,neutral
534361.0,Mid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide,2017-12-05 12:45:00-05:00,GALT,positive
534362.0,Galectin Option Alert: Dec 15 $2 Puts at the Ask: 2000 @ $0.75 vs 6976 OI; Ref=$1.33,2017-12-05 10:21:00-05:00,GALT,positive
534363.0,Mid-Morning Market Update: Markets Mostly Higher; Toll Brothers Misses Q4 Views,2017-12-05 10:15:00-05:00,GALT,negative
534364.0,"Galectin Shares Resume Trade, Down 43% Premarket",2017-12-05 08:46:00-05:00,GALT,positive
534365.0,18 Stocks Moving In Tuesday's Pre-Market Session,2017-12-05 08:34:00-05:00,GALT,neutral
534366.0,Adam Feuerstein Tweets: $GALT study was total fail. Don't be fooled by the spin.,2017-12-05 08:22:00-05:00,GALT,negative
534367.0,Galectin Therapeutics Phase 2b NASH-CX Trial Did Not Meet its Primary Endpoint,2017-12-05 08:16:00-05:00,GALT,neutral
534368.0,"Galectin Therapeutics +40% Premarket @$3.47; Co to Present Results from Phase 2b NASH-CX Trial on December 5, 2017 in 8:30 AM Conference Call",2017-12-05 04:17:00-05:00,GALT,neutral
534369.0,REMINDER: Galectin Will Present Phase 2b NASH-CX Trial Results Dec. 5th On A Conf. Call 8:30am ET,2017-12-04 16:01:00-05:00,GALT,neutral
534370.0,40 Biggest Movers From Wednesday,2017-11-24 05:50:00-05:00,GALT,neutral
534371.0,35 Stocks Moving In Wednesday's Mid-Day Session,2017-11-22 12:25:00-05:00,GALT,neutral
534372.0,40 Biggest Movers From Yesterday,2017-11-22 05:03:00-05:00,GALT,neutral
534373.0,"Galectin Therapeutics Inc. Reports Presentation Of GR-MD-02 Data, Says Objective Response Rate In Advanced Melanoma Was 62.5% In 5 of 8 Subjects",2017-11-13 08:33:00-05:00,GALT,positive
534374.0,Galectin Therapeutics Reports Q3 EPS $(0.13) vs $(0.14) Est.,2017-11-07 08:51:00-05:00,GALT,neutral
534375.0,Galectin Therapeutics Reports Will Present Data Showing Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis At Liver Meeting '17,2017-10-20 08:31:00-04:00,GALT,positive
534376.0,"Roth Capital Initiates Coverage On Galectin Therapeutics with Buy Rating, Announces $8.00 Price Target",2017-10-19 09:09:00-04:00,GALT,neutral
534377.0,"Seaport Global Initiates Coverage On Galectin Therapeutics with Buy Rating, Announces $5.00 Price Target",2017-10-06 09:56:00-04:00,GALT,neutral
534378.0,Galectin Therapeutics Reports Chinese Patent Office To Grant Patent For GR-MD-02,2017-09-12 08:32:00-04:00,GALT,positive
534379.0,"Galectin Therapeutics Issues PR To Provide 'Clarification' To PR Issued Aug. 14th, See Body Text For Revision",2017-08-18 08:36:00-04:00,GALT,neutral
534380.0,"Galectin Therapeutics Q2 EPS $(0.14) vs $(0.15) Est., No Sales",2017-08-14 07:58:00-04:00,GALT,negative
534381.0,Galectin Therapeutics Reports Co. Granted Patent For Enhancing Immunotherapy In Cancer Treatment,2017-07-25 08:32:00-04:00,GALT,negative
534382.0,Galectin Reports Patent For Reducing Inflammatory Response Granted,2017-06-21 08:30:00-04:00,GALT,positive
534383.0,Galectin Therapeutics Reports 'Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial',2017-06-13 08:34:00-04:00,GALT,positive
534384.0,Galectin Issued Autoimmune Disease U.S. Patent For GRM-MD-02,2017-06-06 08:33:00-04:00,GALT,neutral
534385.0,S-3 from Galectin Therapeutics Shows Registration for $100M in Common Shares,2017-05-19 16:20:00-04:00,GALT,positive
534386.0,Galectin Therapeutics Reports Q1 EPS $(0.15) vs $(0.16) Est.,2017-05-15 08:33:00-04:00,GALT,neutral
534387.0,Galectin Reports Received Notice of Japanese Decision to Grant Composition of Matter Patent for GR-MD-02,2017-04-25 08:05:00-04:00,GALT,positive
534388.0,Watch These 5 Huge Put Purchases In Wednesday Trade,2017-04-19 04:48:00-04:00,GALT,positive
534389.0,Benzinga's Option Alert Recap From April 18,2017-04-18 16:19:00-04:00,GALT,positive
534390.0,Option Alert: Galectin Therapeutics Oct17 2.0 Puts Sweep: 550 @  ASK  $0.50: 570 traded vs 161 OI:  Earnings 5/12 Before Open [est]  $3.06 Ref,2017-04-18 11:28:00-04:00,GALT,positive
534391.0,14 Biggest Mid-Day Gainers For Monday,2017-04-10 14:06:00-04:00,GALT,neutral
534392.0,"H.C. Wainwright Holding NASH Investor Conference Today; Attendees Include Allergan, Enanta Pharma, Madrigal Pharma, Vascular Biogenics, Albireo Pharma, CymaBay, Gemphire Therapeutics, And Galectin Therapeutics",2017-04-03 08:28:00-04:00,GALT,neutral
534393.0,15 Biggest Mid-Day Gainers For Thursday,2017-03-30 12:39:00-04:00,GALT,neutral
534394.0,"Benzinga's Top Upgrades, Downgrades For March 30, 2017",2017-03-30 09:42:00-04:00,GALT,positive
534395.0,Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst',2017-03-30 08:46:00-04:00,GALT,positive
534396.0,"H.C. Wainwright Upgrades Galectin Therapeutics to Buy, Raises Price Target to $3.50",2017-03-30 07:12:00-04:00,GALT,neutral
534397.0,Galectin Therapeutics Reports FY16 EPS $(0.76) vs $(0.81) Est.,2017-03-28 08:25:00-04:00,GALT,neutral
534398.0,Galectin Therapeutics Says Top-Line Data Readout For NASH-CX Trial Remains On Track For Early 2017,2017-03-28 08:25:00-04:00,GALT,neutral
534399.0,"Earnings Scheduled For March 28, 2017",2017-03-28 04:54:00-04:00,GALT,neutral
534400.0,"Galectin Therapeutics Issues Statement Regarding GALTW, GALTU",2017-03-23 08:31:00-04:00,GALT,neutral
534401.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-03-16 08:36:00-04:00,GALT,neutral
534402.0,"Galectin Therapeutics Reports GR-MD-02 Showed Clinically Significant Effect in Patients with Severe, Refractory Atopic Dermatitis",2017-03-14 08:48:00-04:00,GALT,negative
534403.0,Galectin Therapeutics GR-MD-02 Efficacy Shows PASI Reduction Of 50% At San Antonio Military Medical Center,2017-03-06 08:31:00-05:00,GALT,neutral
534404.0,Galectin Therapeutics Spikes to High of $1.73 on Volume,2017-02-21 11:12:00-05:00,GALT,neutral
534405.0,18 Biggest Mid-Day Losers For Wednesday,2017-02-15 13:07:00-05:00,GALT,negative
534406.0,Galectin Therapeutics Reports $4 Million in New Equity Financings,2016-12-29 09:01:00-05:00,GALT,neutral
534407.0,Galactin Reports 'Meaningful activity of GR-MD-02 in treating psoriasis and preliminary data in treating atopic dermatitis suggests promise in treatment of serious skin disease',2016-11-10 08:11:00-05:00,GALT,positive
534408.0,12 Biggest Mid-Day Losers For Wednesday,2016-10-05 13:13:00-04:00,GALT,negative
534409.0,Stocks Hitting 52-Week Lows,2016-10-05 10:41:00-04:00,GALT,negative
534410.0,Benzinga's Top Downgrades,2016-10-03 09:08:00-04:00,GALT,positive
534411.0,FBR Capital Downgrades Galectin Therapeutics to Market Perform,2016-10-03 07:36:00-04:00,GALT,neutral
534412.0,12 Biggest Mid-Day Losers For Thursday,2016-09-29 13:10:00-04:00,GALT,negative
534413.0,Galectin Shares Downgraded As NASH-FX Failure Likely Degrades The Prognosis For NASH-CX,2016-09-29 10:26:00-04:00,GALT,negative
534414.0,Benzinga's Top Downgrades,2016-09-29 08:54:00-04:00,GALT,positive
534415.0,H.C. Wainwright Downgrades Galectin Therapeutics to Neutral,2016-09-29 07:05:00-04:00,GALT,neutral
534416.0,Mid-Afternoon Market Update: Dow Gains 80 Points; Crude Oil Up 5%,2016-09-28 15:17:00-04:00,GALT,negative
534417.0,12 Biggest Mid-Day Losers For Wednesday,2016-09-28 13:15:00-04:00,GALT,negative
534418.0,Mid-Day Market Update: U.S. Stocks Turn Lower; Anavex Shares Spike Higher,2016-09-28 12:21:00-04:00,GALT,neutral
534419.0,Why Galectin Therapeutics Just Lost Nearly Half Its Market Cap,2016-09-28 10:59:00-04:00,GALT,negative
534420.0,7 Biggest Price Target Changes For Wednesday,2016-09-28 10:13:00-04:00,GALT,neutral
534421.0,Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Estimates,2016-09-28 10:07:00-04:00,GALT,neutral
534422.0,Benzinga's Top Downgrades,2016-09-28 09:00:00-04:00,GALT,positive
534423.0,"Roth Capital Downgrades Galectin Therapeutics to Sell, Lowers PT to $0.75",2016-09-28 08:25:00-04:00,GALT,negative
534424.0,18 Stocks Moving In Wednesday's Pre-Market Session,2016-09-28 08:21:00-04:00,GALT,neutral
534425.0,"After-Hours Decliners Sept. 27, 2016: GALT Down 46%, TPX 24%, SCSS 10.9%, SONC 6.4%, FOMX 4%, NKE, ARRY 2.6%, FRGI 2%, FL 1.9%, GXP 1.7%, GOOGL 1%",2016-09-27 17:29:00-04:00,GALT,neutral
534426.0,"Galectin Shares Resume Trade, Now Down 29%",2016-09-27 16:45:00-04:00,GALT,positive
534427.0,Galectin Therapeutics Shares to Resume Trade at 4:45 p.m. EDT,2016-09-27 16:21:00-04:00,GALT,positive
534428.0,UPDATE: Galectin Reports Trail Did Not Meet Either Primary Or Secondary Endpoints,2016-09-27 16:18:00-04:00,GALT,neutral
534429.0,UPDATE: Galectin Says Larger Phase 2b Trial in NASH Cirrhosis Now Completely Enrolled,2016-09-27 16:17:00-04:00,GALT,neutral
534430.0,Galectin Therapeutics Reports No Apparent Improvement In 3 Non-Invasive Tesets for Assessment Of Liver Fibrosis,2016-09-27 16:17:00-04:00,GALT,positive
534431.0,8-K from Galectin Therapeutics Shows Securities Purchase Deal with 10X Fund for Aggregate of 1.5M Shares of Series B-3 Convertible Preferred Shares,2016-09-27 16:14:00-04:00,GALT,positive
534432.0,Galectin Therapeutics Shares Halted News Pending,2016-09-27 16:06:00-04:00,GALT,positive
534433.0,Galectin Therapeutics Sells off to Low of $2.33 on Volume,2016-09-26 11:29:00-04:00,GALT,negative
534434.0,15 Stocks Moving In Thursday's Pre-Market Session,2016-09-22 08:26:00-04:00,GALT,neutral
534435.0,15 Biggest Mid-Day Gainers For Wednesday,2016-09-21 12:49:00-04:00,GALT,neutral
534436.0,NASH Sympathy Plays On Tobira Therapeutics Deal,2016-09-20 14:43:00-04:00,GALT,positive
534437.0,"Conatus Pharma Shares Trading Up 27% on the Heels of Deal for Tobira Therapeutics; Also Watching Galmed Pharma, Galectin Therapeutics, Enanta Pharma, Intercept",2016-09-20 10:58:00-04:00,GALT,positive
534438.0,18 Biggest Mid-Day Losers For Thursday,2016-08-25 13:15:00-04:00,GALT,negative
534439.0,Galectin Therapeutics Reports Disappointing Results From 12-Week Extension Of Phase 2A Psoriasis Clinical Trial,2016-08-25 07:56:00-04:00,GALT,negative
534440.0,8-K from Galectin Therapeutics Shows 'Meaningful activity of GR-MD-02 in treating psoriasis...' Demonstrated from 12-Week Extension of Phase 2a Trial,2016-08-25 07:55:00-04:00,GALT,positive
534441.0,Galectin Therapeutics Reports Q2 EPS $(0.20) vs. Est. $(0.24),2016-08-09 08:01:00-04:00,GALT,neutral
534442.0,Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02,2016-08-02 08:45:00-04:00,GALT,neutral
534443.0,"Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis",2016-07-12 08:56:00-04:00,GALT,positive
534444.0,12 Biggest Mid-Day Gainers For Friday,2016-07-01 12:36:00-04:00,GALT,neutral
534445.0,Mid-Morning Market Update: Markets Open Higher; Micron To Lower Jobs,2016-07-01 10:11:00-04:00,GALT,negative
534446.0,Roth Capital Assumes Galectin Therapeutics at Buy,2016-07-01 09:13:00-04:00,GALT,neutral
534447.0,Galectin Therapeutics Reports Positive Preclinical Results On Role Of Galectin-3 In Pulmonary Arterial Hypertension,2016-06-02 08:02:00-04:00,GALT,positive
534448.0,UPDATE: Galectin Therapeutics Says 'Each of the four patients who received six doses of GR-MD-02 over 12 weeks of therapy reported improvement in their symptoms related to psoriasis',2016-05-16 16:06:00-04:00,GALT,positive
534449.0,Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis,2016-05-16 16:05:00-04:00,GALT,positive
534450.0,Galectin Therapeutics Reports Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis,2016-05-11 08:00:00-04:00,GALT,positive
534451.0,GAlectin Therapeutics Reports Q1 EPS $(0.24) vs $(0.17) Est.,2016-05-10 08:03:00-04:00,GALT,neutral
534452.0,"H.C. Wainwright Assumes Galectin Therapeutics at Buy, Announces $8.00 PT",2016-03-28 07:09:00-04:00,GALT,neutral
534453.0,Galectin Therapeutics Reports FY15 EPS $(0.88) vs. Prior Year Quarter $(0.78),2016-03-15 08:00:00-04:00,GALT,neutral
534454.0,Galectin Therapeutics Reports FY15 EPS $(0.88) vs $(0.78) in Same Qtr. Last Year,2016-03-15 07:46:00-04:00,GALT,neutral
534455.0,Roth's Piros: Galectin Therapeutics Shares Can Quadruple In Next 12 Months,2016-03-09 15:00:00-05:00,GALT,positive
534456.0,Galectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis,2016-02-24 08:31:00-05:00,GALT,positive
534457.0,"8-K from Galectin Therapeutics Shows Co. Received Dismissals of Federal Securities Class Action, Holder Derivative Actions",2016-01-05 08:10:00-05:00,GALT,positive
534458.0,"CVI Investments Reports 5.5% Passive Stake In Galectin Therapeutics as of November 20, 2015",2015-11-27 10:00:00-05:00,GALT,positive
534459.0,Morning Market Losers,2015-11-20 10:06:00-05:00,GALT,negative
534460.0,"Galectin Therapeutics Prices $9.8M Registered Direct Offering: to Purchase ~3.57M Shares of Common at Exercise Price $2.50/Share, ~4.762M Shares at $2.06/Share",2015-11-20 09:02:00-05:00,GALT,positive
534461.0,Galectin Reports Q3 EPS $(0.26) vs $(0.20) Est.,2015-11-09 08:07:00-05:00,GALT,neutral
534462.0,UPDATE: Galectin Says Co. Filed NDA Application for GR-MD-02 In Combo with Keytruda with FDA,2015-10-19 07:54:00-04:00,GALT,neutral
534463.0,8-K from Galectin Therapeutics Shows GR-MD-02 Will Be Studied in Combo with Keytruda in Patients with Metastatic Melanoma,2015-10-19 07:54:00-04:00,GALT,neutral
534464.0,Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference,2015-10-07 16:09:00-04:00,GALT,neutral
534465.0,Galectin Therapeutics Still A Favorite Pick Of H.C. Wainwright Analysts,2015-09-28 14:11:00-04:00,GALT,positive
534466.0,Galectin Therapeutics Reports Commencement of Phase 2a Psoriasis Study with GR-MD-02,2015-09-24 08:00:00-04:00,GALT,neutral
534467.0,Galectin Therapeutics Could Triple On Fibrosis And Cirrhosis Treatment,2015-09-21 10:13:00-04:00,GALT,neutral
534468.0,Benzinga's Top Initiations,2015-09-21 10:11:00-04:00,GALT,positive
534469.0,Morning Market Gainers,2015-09-21 09:42:00-04:00,GALT,neutral
534470.0,"H.C. Wainwright Initiates Coverage on Galectin Therapeutics at Buy, Announces $7.00 PT",2015-09-21 07:06:00-04:00,GALT,neutral
534471.0,Galectin Therapeutics Announces Start of Phase 2 Clinical Trial with GR-MD-02 in NASH with Advanced Fibrosis,2015-09-16 07:58:00-04:00,GALT,positive
534472.0,"Mid-Day Market Update: Thursday's Movers, China, Tesla And More",2015-08-13 13:09:00-04:00,GALT,neutral
534473.0,Morning Market Gainers,2015-08-13 09:45:00-04:00,GALT,neutral
534474.0,Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases,2015-08-13 08:00:00-04:00,GALT,neutral
534475.0,Galectin Therapeutics Reports Q2 :pss $0.21 Vs est Loss $0.23,2015-08-10 08:08:00-04:00,GALT,negative
534476.0,"Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development",2015-07-15 16:11:00-04:00,GALT,neutral
534477.0,Galectin Therapeutics Begins Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis,2015-06-29 07:45:00-04:00,GALT,neutral
534478.0,Galectin Therapeutics Announces no Drug-Drug Interaction Between GR-MD-02 and Midazolam,2015-05-14 08:04:00-04:00,GALT,negative
534479.0,Filing from Galectin Therapeutics Shows Q1 Loss of $0.22/Share vs Loss of $0.20/Share Est.,2015-05-11 07:51:00-04:00,GALT,negative
534480.0,Galectin Therapeutics Presents Research With GR-MD-02 in NASH at AASLD,2015-03-24 08:07:00-04:00,GALT,neutral
534481.0,Galectin Therapeutics Reports FY14 GAAP EPS $(0.78) vs. Est. $(0.77),2015-03-18 16:23:00-04:00,GALT,neutral
534482.0,Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH,2015-03-12 08:18:00-04:00,GALT,positive
534483.0,"8-K from Galectin Therapeutics Offers Details from Design of Phase 2 Trial with GR-MD-02, Says Will Submit an SPA by Month End",2015-02-24 07:57:00-05:00,GALT,neutral
534484.0,Galectin Therapeutics Halted on Up Down Limit,2015-01-08 14:15:00-05:00,GALT,neutral
534485.0,Morning Market Gainers,2015-01-07 09:38:00-05:00,GALT,neutral
534486.0,Wednesday Morning Movers,2015-01-07 09:17:00-05:00,GALT,neutral
534487.0,Galectin Therapeutics Shares Rise 46% Premarket on Positive Phase 1 for GR-MD-02,2015-01-07 08:13:00-05:00,GALT,positive
534488.0,Galectin Therapeutics Announces Phase 1 Trial Shows Drug Safe For Fibrosis and May Have Therapeutic Effects,2015-01-07 08:02:00-05:00,GALT,positive
534489.0,Stocks Hitting 52-Week Lows,2014-12-24 10:12:00-05:00,GALT,negative
534490.0,Galectin Therapeutics Inc. Reports Q3 EPS of $(0.17) vs $(0.27) Est,2014-11-10 08:20:00-05:00,GALT,neutral
534491.0,Galectin Therapeutics' Phase 1 Data Advances GR-MD-02 Into Phase 2 Clinical Development,2014-11-09 15:46:00-05:00,GALT,neutral
534492.0,MLV & Co Has Positive Outlook On Galectin Therapeutics Inc,2014-09-16 09:56:00-04:00,GALT,positive
534493.0,Galectin Confirms Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy ,2014-09-15 08:06:00-04:00,GALT,neutral
534494.0,Galectin Issued Patent for GR-MD-02,2014-09-15 07:53:00-04:00,GALT,neutral
534495.0,8-K from Galectin Therapeutics Shows Slideshow Presentation: Shows 'Ongoing Discussions with Large Pharma Cos.',2014-09-12 15:15:00-04:00,GALT,neutral
534496.0,Galectin Shares Move to High on Volume,2014-08-20 14:40:00-04:00,GALT,positive
534497.0,"Galectin Therapeutics CEO Traber Buys 4,000 Shares @$4.46/Share",2014-08-15 09:08:00-04:00,GALT,positive
534498.0,Galectin Therapeutics Inc. Reports Q2 EPS of $(0.17) vs $(0.21) Est,2014-08-07 17:24:00-04:00,GALT,neutral
534499.0,UPDATE: Galectin Awarded U.S. Patent for GR-MD-02 Composition of Matter ,2014-08-05 08:15:00-04:00,GALT,positive
534500.0,Galectin Announces Patent For GR-MD-02,2014-08-05 08:05:00-04:00,GALT,neutral
534501.0,Galectin Statement About Class Action Lawsuit,2014-08-04 08:05:00-04:00,GALT,negative
534502.0,UPDATE: Aegis Capital Downgrades Galectin Therapeutics,2014-08-01 12:26:00-04:00,GALT,neutral
534503.0,"Galectin Issues Statement on Yesterday's Sell Off, Says Attributed To Negative Social Media Posts and Misinterpretation",2014-07-30 09:09:00-04:00,GALT,negative
534504.0,UPDATE: Galectin Says Market Reacted Negatively to Positive Results of Clinical Trial ,2014-07-30 09:09:00-04:00,GALT,positive
534505.0, Galectin Therapeutics Issues Statement on GR-MD-02 Development Program,2014-07-30 09:08:00-04:00,GALT,neutral
534506.0,UPDATE: MLV & Co Reiterates On Galectin Therapeutics Following Cohort 2 Results,2014-07-30 07:41:00-04:00,GALT,neutral
534507.0,Morning Market Losers ,2014-07-29 09:54:00-04:00,GALT,negative
534508.0,UPDATE: Galectin Slideshow Reveals Several Concerning Points,2014-07-29 08:47:00-04:00,GALT,neutral
534509.0,UPDATE: Galectin Shares Fall 32% Premarket Following Release of 8-K,2014-07-29 08:41:00-04:00,GALT,positive
534510.0,"8-K from Galectin Shows GR-MD-02 Was Safe, Well Tolerated in Recent Trial, Primary Endpoints in Cohort 2 Were Met",2014-07-29 08:22:00-04:00,GALT,positive
534511.0,Galectin Shares Move Lower; May be Attributed to Seeking Alpha Post,2014-07-28 10:34:00-04:00,GALT,neutral
534512.0,"Adam Feuerstein Tweet: After spending time with $ICPT NASH study this week for Mailbag, $GALT NASH trial is farce by comparison.",2014-07-25 14:01:00-04:00,GALT,negative
534513.0,Galectin Will Host Webcase to Discuss Phase 1 GR-MD-02 Findings,2014-07-25 08:02:00-04:00,GALT,neutral
534514.0,Galectin Therapeutics Reports First Patient Dosed in Cohort 1 of Phase 1B Clincial Trial of GR-MD-02 in Combo with Ipilimumab in Metastatic Melanoma,2014-07-22 08:32:00-04:00,GALT,neutral
534515.0,"Galectin Offers Results in Preclinical Model of GR-MD-02, Results Show Significant Disease Improvement",2014-06-23 08:06:00-04:00,GALT,positive
534516.0,Galectin Announces Receiving of US Patent for GR-MD-02,2014-05-28 07:39:00-04:00,GALT,neutral
534517.0,Galectin Revives Patent For GR-MD-02,2014-05-28 07:37:00-04:00,GALT,positive
534518.0,Galectin Therapeutics Inc. Reports Q1 EPS of $(0.27) vs $(0.20) Est,2014-05-13 17:02:00-04:00,GALT,neutral
534519.0,Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02,2014-04-23 08:02:00-04:00,GALT,neutral
534520.0,Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis; Exoects GR-MD-02 Phase 1 Cohort 2 Result at End of July,2014-04-17 10:23:00-04:00,GALT,positive
534521.0,"McNicoll Lewis Vlak Maintains Buy on Galectin Therapeutics Inc., Raises PT to $27.00",2014-04-02 08:14:00-04:00,GALT,neutral
534522.0,MLV & Co Expects Positive News from Galectin Therapeutics,2014-04-01 09:03:00-04:00,GALT,positive
534523.0,Galectin Announces First Cohort Results in Phase 1 Trial Shows GR-MD-02 Safe and Well Tolerated in Patients,2014-03-31 16:32:00-04:00,GALT,positive
534524.0,Adam Feuerstein Tweet: '$GALT: Mark The Date. Drug Data Are Coming and We're Selling Stock',2014-03-25 13:40:00-04:00,GALT,neutral
534525.0,Benzinga's Volume Movers,2014-03-25 10:26:00-04:00,GALT,neutral
534526.0,Galectin Therapeutics to Announce Results from First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease ,2014-03-25 08:01:00-04:00,GALT,neutral
534527.0,Form 8-K from Galectin Shows Will Report Data on First Cohort in Fatty Liver Disease in Conf. Call on Apr. 1st,2014-03-25 08:00:00-04:00,GALT,neutral
534528.0,Galectin Therapeutics Inc. Reports FY EPS of $(1.30) vs $(1.29) Est,2014-03-21 16:47:00-04:00,GALT,neutral
534529.0,Form 8-K from Galectin Therapeutics Shows Received Patent for GR-MD-02 in Fatty Liver Disease,2014-02-26 07:48:00-05:00,GALT,neutral
534530.0,Galectin Therapeutics Awarded NASH-Related Patent,2014-02-25 09:35:00-05:00,GALT,positive
534531.0,"Aegis Capital Maintains Buy on Galectin Therapeutics Inc., Raises PT to $32.00",2014-02-12 11:17:00-05:00,GALT,neutral
534532.0,UPDATE: Galectin Expects Trial to Begin Enrollment In March,2014-02-03 11:32:00-05:00,GALT,neutral
534533.0,"Galectin Therapeutics, Providence Portland Medical Center Receive OK from FDA to Proceed with Phase 1B Clinical Trial in Metastatic Melanoma ",2014-02-03 10:59:00-05:00,GALT,positive
534534.0,"UPDATE: Galectin Therapeutics, SBH Sciences from Galectin Sciences",2014-01-27 08:17:00-05:00,GALT,neutral
534535.0,"Galectin, SBH Sciences in Venture",2014-01-27 08:08:00-05:00,GALT,neutral
534536.0,Galectin Therapeutics Spikes Higher,2014-01-21 14:41:00-05:00,GALT,neutral
534537.0,Galectin Therapeutics Supports IND for GR-MD-02 in Metastatic Melanoma,2014-01-15 08:04:00-05:00,GALT,positive
534538.0,UPDATE: Galectin Therapeutics Supports Investigational New Drug Application for its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma,2014-01-15 07:55:00-05:00,GALT,positive
534539.0,Galectin Therapeutics: IND Submitted by Providence Portland Medical Center,2014-01-15 07:51:00-05:00,GALT,neutral
534540.0,Galectin Therapeutics Complet Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Patients with NASH,2014-01-13 08:05:00-05:00,GALT,neutral
534541.0,"Market Wrap For January 10: Job Growth Weak, But Unemployment Falls",2014-01-10 16:53:00-05:00,GALT,negative
534542.0,Benzinga's Volume Movers,2014-01-10 10:26:00-05:00,GALT,neutral
534543.0,Galectin Sold 2.39M Shares at $9.99/Share,2014-01-10 08:06:00-05:00,GALT,positive
534544.0,Adam Feuerstein Tweet: 'I've never heard of Stonegate Securities but disclosures B & C on this $GALT report are refreshingly honest --> pic.twitter.com/w8Zkl9KJYE',2013-11-26 06:59:00-05:00,GALT,positive
534545.0,Galectin Therapeutics Inc. Reports Q3 EPS of $(0.22) vs $(0.20) Est,2013-11-12 08:14:00-05:00,GALT,neutral
534546.0,Galectin Therapeutics Inc. Reports Q3 EPS of $(0.22) vs $(0.20) Est,2013-11-12 08:14:00-05:00,GALT,neutral
534547.0,Galectin Therapeutics Could Sell Up to $30M in Shares,2013-10-25 17:18:00-04:00,GALT,positive
534548.0,"Galectin Announces Early Warrant Exercise by 10X Fund, Issues Update on Cash Position",2013-10-17 08:09:00-04:00,GALT,neutral
534549.0,UPDATE: Ascendiant Capital Initiates Coverage on Galectin Therapeutics on Intriguing Speculative Short-Cap Investment Story,2013-10-07 10:55:00-04:00,GALT,positive
534550.0,Benzinga's Top Initiations,2013-10-07 07:49:00-04:00,GALT,positive
534551.0,"Ascendiant Capital Initiates Coverage on Galectin Therapeutics Inc. at Buy, Announces $13.00 PT",2013-10-07 06:38:00-04:00,GALT,neutral
534552.0,"Trading Halts on GALT, BOTJ, AMU, LIQD, and WINA",2013-09-26 09:31:00-04:00,GALT,neutral
534553.0,Benzinga's Volume Movers,2013-09-12 10:43:00-04:00,GALT,neutral
534554.0,Morning Market Movers ,2013-09-12 10:11:00-04:00,GALT,neutral
534555.0,Benzinga's Volume Movers,2013-09-11 10:45:00-04:00,GALT,neutral
534556.0,"Galectin Therapeutics Reports $3M Placement of Restricted Stock, Priced 500K Shares at $6/Share",2013-08-21 08:04:00-04:00,GALT,negative
534557.0,UPDATE: Aegis Capital Raises PT on Galectin Therapeutics Following Valuation Update,2013-08-19 11:26:00-04:00,GALT,neutral
534558.0,Morning Market Movers ,2013-08-12 10:13:00-04:00,GALT,neutral
534559.0,Galectin Therapeutics Reports FDA Fast Track Designation for GR-MD-02,2013-08-12 08:04:00-04:00,GALT,neutral
534560.0,"Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis",2013-07-24 08:31:00-04:00,GALT,positive
534561.0,Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis ,2013-07-01 08:07:00-04:00,GALT,positive
534562.0,Galectin Therapeutics Names Industry-Veteran Jack W. Callicutt Chief Financial Officer ,2013-06-21 08:01:00-04:00,GALT,neutral
534563.0,"Benzinga's Small Cap Movers for Tuesday March 5, 2013",2013-03-05 18:38:00-05:00,GALT,neutral
534564.0,Aegis Capital Reiterates Buy Rating on Galectin Therapeutics After FDA Approval,2013-03-05 10:37:00-05:00,GALT,positive
534565.0,Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with University of Georgia,2013-02-19 09:01:00-05:00,GALT,neutral
534566.0,Galectin Therapeutics Submits IND Application for Treatment of Fatty Liver Disease,2013-01-31 09:02:00-05:00,GALT,neutral
534567.0,Galectin Therapeutics Publishes Proceeds by ACS on Symposium,2013-01-28 09:04:00-05:00,GALT,neutral
534568.0,Galectin Therapeutics Says Anti-Galectin Drug Effective in Preclinical Studies,2013-01-22 09:04:00-05:00,GALT,positive
534569.0,Galectin Therapeutics Reports Q3 EPS $-0.19 vs $-0.18 Est,2012-11-09 16:04:00-05:00,GALT,neutral
534570.0,Galectin Therapeutics Names Shlevin COO,2012-08-29 09:01:00-04:00,GALT,neutral
534571.0,Aegis Capital Initiates Coverage on Galectic Therapeutics at Buy,2012-07-25 07:59:00-04:00,GALT,neutral
534572.0,Galectin Therapeutics Pops 50% on U.S. Patent,2012-07-23 09:57:00-04:00,GALT,neutral
534573.0,Galectin Therapeutics Halted on Circuit Breaker ,2012-07-23 09:52:00-04:00,GALT,neutral
534574.0,Galectin Therapeutics Receives U.S. Patent for Potential Ground-Breaking Treatment for Chronic Liver Disease with Fibrosis and Cirrhosis   ,2012-07-23 09:48:00-04:00,GALT,neutral
534575.0,"UPDATE: Dawson James Reiterates Buy Rating, Lowers PT on Galectin Therapeutics",2012-07-06 11:00:00-04:00,GALT,negative
534576.0,"Dawson James Maintains Galectin Therapeutics at Buy, Lowers PT to $3",2012-07-06 09:13:00-04:00,GALT,negative
534577.0,Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders,2012-05-22 09:00:00-04:00,GALT,neutral
534578.0,"From Earlier: Galectin Therapeutics Announces Pricing of Public Offering of 1.16M Units, Listing on Nasdaq and Effectiveness of Reverse Stock Split  ",2012-03-23 07:27:00-04:00,GALT,neutral
